Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Front Oncol ; 12: 961902, 2022.
Article in English | MEDLINE | ID: mdl-36713506

ABSTRACT

Objective: Retrospectively analyzed the esophageal carcinoma (EC) patients with esophageal perforation (EP) after radiotherapy to discuss the treatment and prognosis. Methods: Data of patients with EC who had EP after radiotherapy in Hebei Cancer Hospital were collected from 2001 to 2020 and retrospectively analyzed. All analyses were performed using SPSS Statistics for Windows, version 18. 0 (SPSS Inc., Chicago, Ill., USA). P values less than 0.05 were considered statistically significant. Results: A total of 94 patients with EC were enrolled, among which 72 were males and 22 were females, with a median age of 62 (38-82) years. The tumor was located in the upper thoracic in 45 patients, middle thoracic in 45 patients, and lower thoracic in 4 patients. There were 30 cases of tracheoesophageal fistula (TEF) and 64 cases of esophagomediastinal fistula (EMF). All patients died within 11 months (median: two months) after EP. After EP, 48 patients were treated by tube feeding (include nasal feeding and gastrostomy), 26 patients by esophageal stenting, and 20 patients by fluid infusion therapy, and their one, three, and six months survival rates after EP were 81.3%, 31.3%, and 12.5% (P = 0.000). In the TEF group, the one, three, and six month survival rates after EP of tube feeding, esophageal stenting and fluid infusion groups were 88.2%, 17.6%, 11.8%; 45.5%, 27.3%, 0%; and 50.0%, 50.0%, 0% (P = 0.345). In the EMF group, the one, three, and six months survival rates after EP of this three groups were 77.4%, 38.7%, 12.9%; 26.7%, 20.0%, 6.7%; and 22.2%, 11.1%, 0% (P=0.002), respectively. Conclusion: Most patients with EP after radiotherapy died within six months, with low survival and poor prognosis. Tube feeding therapy can achieve relatively good survival, especially for patients with EMF. The survival of patients treated by tube feeding therapy is significantly better than the survival of those treated by other methods.

2.
Chinese Journal of Cancer ; (12): 325-329, 2010.
Article in English | WPRIM (Western Pacific) | ID: wpr-292586

ABSTRACT

<p><b>BACKGROUND AND OBJECTIVE</b>Research has confirmed that transforming growth factor-beta1 (TGF-beta1) is one of the cytokines related to radiation pneumonitis. But the level of TGF-beta1 in serum needed to predict radiation pneumonitis is still not clear. This study assessed the value of TGF-beta1 in both serum and induced sputum in predicting radiation pneumonitis, providing a reference for the radiotherapy of patients with non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>A total of 23 patients with NSCLC treated with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) in our department between November 2007 and January 2009 were analyzed and evaluated. TGF-beta1 levels in both serum and sputum were detected before and near the end of radiotherapy for all the patients. The TGF-beta1 level in serum was measured with enzyme-linked immunosorbent assay (ELISA). Immunocytochemistry assays were used to detect TGF-beta1 expression in sputum sediment. Radiation pneumonitis was graded according to Radiation Therapy Oncology Group (RTOG) radiation scoring criteria every 3 weeks from the start to 3 months after the end of treatment.</p><p><b>RESULTS</b>Radiation pneumonitis was noted in 9 patients in this cohort. The total incidence of radiation pneumonitis was 39.1% (9/23) and those with Grade II or worse was 30.4% (7/23). The absolute TGF-beta1 level in serum after radiotherapy was higher than before radiotherapy, but there was no statistical difference (P = 0.139). Patients with increased levels of TGF-beta1 had a higher incidence of radiation pneumonitis (45.5%) than those with decreased TGF-beta1 levels post-radiotherapy (40.0%). Though there was a tendency of higher incidence of radiation pneumonitis with increases in TGF-beta1 level, no statistical difference was found (P = 1.000). Patients with tumor response had higher incidence of radiation pneumonitis (50.0%) than patients without when TGF-beta1 levels in serum increased, but there was no statistical difference (P = 0.792). TGF-beta1 was positively expressed (brown yellow) in sputum on immunocytochemistry assays and located in the cytoplasm of either macrophages or epithelial cells. Macrophages were the main cells expressing TGF-beta1. A significantly higher positive expression rate (71.4%) was found in sputum post-radiotherapy than pre-radiotherapy (28.6%) (P = 0.015). The higher incidence of radiation pneumonitis (46.7%) was found in patients with positive TGF-beta1 expression in sputum post-radiotherapy than those with negative expression post-radiotherapy (14.3%) (P = 0.193).</p><p><b>CONCLUSION</b>It may be more reasonable to predict radiation pneumonitis by combining the change of TGF-beta1 levels in serum with tumor response than just the change of TGF-beta1 levels in serum alone. TGF-beta1 can positively express in the sputum of patients with NSCLC, located in macrophages and epithelial cells, with macrophages as the main areas of expression. Patients with positively expressed TGF-beta1 in sputum after radiotherapy have a higher incidence of radiation pneumonitis than those with negative expressions. The positive expression of TGF-beta1 in sputum is expected to become a factor for predicting radiation pneumonitis.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Carcinoma, Non-Small-Cell Lung , Blood , Metabolism , Radiotherapy , Follow-Up Studies , Lung Neoplasms , Blood , Metabolism , Radiotherapy , Macrophages , Metabolism , Radiation Pneumonitis , Blood , Metabolism , Radiotherapy, Conformal , Radiotherapy, Intensity-Modulated , Sputum , Chemistry , Transforming Growth Factor beta1 , Blood , Metabolism
3.
Chinese Journal of Cancer ; (12): 436-440, 2010.
Article in English | WPRIM (Western Pacific) | ID: wpr-292565

ABSTRACT

<p><b>BACKGROUND AND OBJECTIVE</b>The role of adjuvant radiotherapy to the regional nodes in women with T1 to T2 breast cancer and one to three positive nodes is controversial. This study compared and analyzed the prognosis of patients with T1-T2 breast cancer with one to three positive nodes after modified radical mastectomy with or without postoperative radiotherapy.</p><p><b>METHODS</b>The cases of 434 women patients with T1 to T2 breast cancer with one to three positive lymph nodes after modified radical mastectomy were reviewed, of which 196 patients received postoperative radiotherapy and 238 patients did not. The ipsilateral chest wall and supraclavicular fossa were irradiated with doses of 46-50 Gy in 23-25 fractions.</p><p><b>RESULTS</b>For all patients, the 3- and 5-year rates of overall survival (OS) were 94.7% and 85.7% respectively, local control (LC) 96.5% and 95.6%;, and disease-free survival (DFS) 89.3% and 82.3% respectively. The 3- and 5-year OS rates for patients without radiotherapy were 92.7% and 97.1% and for those with radiotherapy were 82.4% and 89.2%, both with significant differences (P = 0.039). The 3- and 5-year LC rates for patients without radiotherapy were 94.8% and 98.4% and for those with radiotherapy were 93.6% and 97.7%, again with significant differences (P = 0.041). The 3- and 5-year DFS rates for patients without radiotherapy were 87.8% and 91.3% and for patients with radiotherapy were 78.5% vs 86.1% (P = 0.047).</p><p><b>CONCLUSIONS</b>Postoperative radiotherapy confers better rates of OS, LC, and DFS in patients with T1 to T2 breast cancer with one to three positive nodes after modified radical mastectomy.</p>


Subject(s)
Female , Humans , Middle Aged , Breast Neoplasms , Pathology , Radiotherapy , General Surgery , Carcinoma, Ductal, Breast , Pathology , Radiotherapy , General Surgery , Carcinoma, Lobular , Pathology , Radiotherapy , General Surgery , Disease-Free Survival , Follow-Up Studies , Lymph Node Excision , Lymphatic Metastasis , Mastectomy, Modified Radical , Neoplasm Recurrence, Local , Neoplasm Staging , Radiotherapy, Adjuvant , Radiotherapy, High-Energy , Retrospective Studies , Survival Rate
4.
Chinese Journal of Cancer ; (12): 873-881, 2010.
Article in English | WPRIM (Western Pacific) | ID: wpr-296342

ABSTRACT

<p><b>BACKGROUND AND OBJECTIVE</b>Many patterns of treatment have been used to treat esophageal carcinoma in the past years, however, an optimal treatment is still the key issue to be explored. Therefore, we analyzed the published literature about radiotherapy for esophageal cancer in recent 15 years in China, and observed the survival rate, local control rate, adverse events, and so on.</p><p><b>METHODS</b>A total of 56 eligible papers about radiotherapy for esophageal squamous cell carcinoma published in Chinese core periodicals between 1994 and 2009 were selected. The survival rates, local control rates, and adverse events were analyzed.</p><p><b>RESULTS</b>The 1-, 2-, 3-, and 5-year overall survival rates of the patients reported in the 56 papers were (67.99 ± 12.55)%, (49.59 ± 11.79)%, (34.50 ± 11.49)%, and (23.31 ± 10.21)%, respectively. The 1-, 2-, 3-, and 5-year local control rates were (73.04 ± 13.37)%, (61.60 ± 15.50)%, (51.77 ± 15.00)%, and (50.15 ± 21.36)%, respectively. The acute esophageal toxicity rate was (44.84 ± 25.71)% in 32 papers reported in recent 15 years, and the acute esophageal toxicity over grade II accounted for (35.93 ± 22.90)%. The rates of acute esophageal toxicity were (26.84 ± 13.12)% for conventional radiation, (53.72 ± 21.82)% for late course accelerated hyperfractionation radiation, (61.33 ± 28.69)% for concurrent chemoradiotherapy, and (40.31 ± 27.22)% for other ways of radiation. The late toxicity rate described in 23 papers was (5.13 ± 4.07)% in recent 15 years. The late toxicity rates were (5.66 ± 3.42)% for conventional radiation, (4.53± 4.07)% for late course accelerated hyperfractionation radiation, (2.24±1.31)% for concurrent chemoradiotherapy, and (7.34 ± 5.06)% for other ways of radiation. The Meta analysis indicated that concurrent chemoradiotherapy was better than late course accelerated hyperfractionation radiation and conventional radiation.</p><p><b>CONCLUSIONS</b>The long-term survival of patients with esophageal cancer is still disappointed in recent years. Concurrent chemoradiotherapy shows advantages in treating esophageal cancer and, currently, is the best non-surgical treatment of esophageal cancer.</p>


Subject(s)
Humans , Carcinoma, Squamous Cell , Drug Therapy , Radiotherapy , Chemoradiotherapy , Methods , China , Dose Fractionation, Radiation , Esophageal Neoplasms , Drug Therapy , Radiotherapy , Esophagitis , Radiation Injuries , Radiotherapy , Methods , Survival Rate
5.
Journal of Medical Biomechanics ; (6): 112-117, 2009.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-737265

ABSTRACT

A review of cell traction forces (CTFs) measurement based on Biological MiCro Electromechanical Systems (BioMEMS) microposts matrix is presented.CTFs are exerted by cells and ansmitted to the underly-ing substrate through focal adhesions and close contacts.which is essential for cells movement.Cells probe the mechanicaI compliance of the exlracellular mabix (ECM) in part by locally deforming it with nanonewton-scale traction forces.Precision measurement of CTFs is significant for many researches such as call biology and tissue engineering and so on.Enabled by the advancement in BioMEMS technology,surface treated high aspeect ratio Polydimethyisiloxane(PDMS)micropos matrix devices,which serve as BioMEMS sensom for de-tecting cellular nanoforces and studying in vitro cell mechanics,have been developed.Closely spaced vartical microposts matrixes were designed to encourage cells to attach and spread across multiple microposts,and to bend the microposts like vertical cantilevers as the cells locomote on the surface.Using this dense and dis-crete matrix of microposts rather than a convanfional continuous substrate,CTFs can be directly measured and quantified by processing the microscopy images of the deformations of microposts.The resolution of the force was in tens of nN/μm scale.At first,the conventional CTFs measurement methods were concisely summa-rized.Then BioMEMS microposts matrix method was described in detail,including principle and fabfication process,Surface treatment and cell expedment results.Furthermore,high aspect ratio structure collapse prob-lem was investigated.

6.
Journal of Medical Biomechanics ; (6): 112-117, 2009.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-735797

ABSTRACT

A review of cell traction forces (CTFs) measurement based on Biological MiCro Electromechanical Systems (BioMEMS) microposts matrix is presented.CTFs are exerted by cells and ansmitted to the underly-ing substrate through focal adhesions and close contacts.which is essential for cells movement.Cells probe the mechanicaI compliance of the exlracellular mabix (ECM) in part by locally deforming it with nanonewton-scale traction forces.Precision measurement of CTFs is significant for many researches such as call biology and tissue engineering and so on.Enabled by the advancement in BioMEMS technology,surface treated high aspeect ratio Polydimethyisiloxane(PDMS)micropos matrix devices,which serve as BioMEMS sensom for de-tecting cellular nanoforces and studying in vitro cell mechanics,have been developed.Closely spaced vartical microposts matrixes were designed to encourage cells to attach and spread across multiple microposts,and to bend the microposts like vertical cantilevers as the cells locomote on the surface.Using this dense and dis-crete matrix of microposts rather than a convanfional continuous substrate,CTFs can be directly measured and quantified by processing the microscopy images of the deformations of microposts.The resolution of the force was in tens of nN/μm scale.At first,the conventional CTFs measurement methods were concisely summa-rized.Then BioMEMS microposts matrix method was described in detail,including principle and fabfication process,Surface treatment and cell expedment results.Furthermore,high aspect ratio structure collapse prob-lem was investigated.

7.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-679453

ABSTRACT

Objective To compare and analyze the effect of prophylactic postoperative radiotherapy for esophageal carcinoma.Methods 102 such patients were treated with prophylactic radiotherapy after radical resection,to a total dose of 50-60 Gy.The extensive portal included supraclavicular region on both sides,entire mediastinum,the site of anastomosis and left gastric lymph node region in 43 patients.The re- gional portal range was different according to the different location of primary lesion in 59 patients.Results The 1-,3- and 5-year survival rate was 76%,51% and 43% respectively,with a median survival of 30 months.The 1-,3- and 5-year survival rate was 77%,52% and 41% in the extensive portal and 76%, 49% and 45% in the regional portal,respectively(P=0.884).According to multivariate analysis,N stage, number of metastatic lymph nodes and tumor length were independent prognostic factors.Conclusions Regional portal does not lower the survival rate when prophylactic postoperative radiotherapy is used in e- sophageal carcinoma.

8.
Di Yi Jun Yi Da Xue Xue Bao ; 22(7): 620-3, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12376292

ABSTRACT

OBJECTIVE: To construct a recombinant eukaryotic expression plasmid containing rhoptry protein 2 (ROP2) gene of Toxoplasma gondii. METHOD: The truncated ROP2 gene was amplified from the genomic DNA of Toxoplasma gondii RH strain and cloned into plasmid pGEX-4T-1. The PCR product was subcloned into an eukaryotic expression plasmid pcDNA3 which was identified by enzyme digestion and PCR amplification. Sequence analysis of the insert in the recombinant plasmid was performed by Sanger's method. RESULTS: The amplified DNA fragment was about 1043 bp in length, with identical sequence with the published ROP2 gene sequence. Enzyme digestion and PCR analysis showed that the truncated ROP2 gene had been successfully cloned into plasmid pGEX-4T-1 and pcDNA3. CONCLUSION: The truncated ROP2 gene of Toxoplasma gondii has been amplified and cloned into the eukaryotic expression plasmid pcDNA3.


Subject(s)
Membrane Proteins/genetics , Protozoan Proteins/genetics , Toxoplasma/genetics , Animals , Base Sequence , DNA, Protozoan/analysis , Eukaryotic Cells/metabolism , Gene Amplification , Gene Expression , Membrane Proteins/biosynthesis , Molecular Sequence Data , Plasmids/genetics , Protozoan Proteins/biosynthesis , Transfection
9.
Di Yi Jun Yi Da Xue Xue Bao ; 22(4): 335-7, 2002 Apr.
Article in Chinese | MEDLINE | ID: mdl-12390738

ABSTRACT

KR-100 is a newly developed long-lasting insecticide that incorporates cinerins substance, drug-release control substance and synergistic agent following certain procedures under carefully regulated conditions. Tests of the efficacy, toxicity, stability and long-term effect of KR-100 were conducted, and it was show that the insecticide possessed strong and long-lasting effect against mosquitoes, flies and cockroaches but was by no means toxic to human. Morphological study of KR-100 under scanning electron microscope revealed porous membrane form. This insecticide, therefore, can be safely applied with good pesticidal effect.


Subject(s)
Cockroaches/drug effects , Culicidae/drug effects , Diptera/drug effects , Insecticides/pharmacology , Methaqualone/analogs & derivatives , Methaqualone/pharmacology , Animals , Drug Stability , Insecticides/toxicity , Methaqualone/toxicity , Mice , Models, Animal , Temperature , Water/chemistry
10.
Di Yi Jun Yi Da Xue Xue Bao ; 22(6): 499-502, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12297467

ABSTRACT

OBJECTIVE: To clone the defensin genes from the Chinese main mosquito vectors and conduct sequnce analysis. METHODS: The genomic DNA and total RNA were extracted from Aedes aegypti, Aedes albopictus, Culex fatigans and Anopheles sinensis respectively, followed by PCR and reverse transcriptase-PCR with 2 pairs of primers designed and synthesized on the basis of reported defensin gene sequence. Purification and sequence analysis of the PCR products derived from the above procedure were conducted. RESULTS: The products with predicted size were amplified from the genomic DNA of A.aegypti, A.albopictus and A.sinensis. Sequence analysis showed that the amplified fragments from A.aegypti and A.albopictus, but not that from A.sinensis, were highly homologous with the reported defensin sequence. CONCLUSION: The defensin gene of A.aegypti and A.albopictus have been successfully cloned, and the homology of defensin genes among different mosquitoes is parallel to their genetic distances.


Subject(s)
Aedes/genetics , Anopheles/genetics , Culex/genetics , Defensins/genetics , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , DNA, Complementary , Molecular Sequence Data , Polymerase Chain Reaction/methods , Sequence Analysis, DNA , Sequence Homology, Nucleic Acid
11.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-679339

ABSTRACT

Objective To define the maximum-tolerated dnse(MTD)and observe the side effect of escalating cisplatin with 5-fluorouracil in concurrent chemoradiotherapy for esophageal carcinoma in Chinese,with toxicity studied.Methods Previously untreated fifteen Chinese patients suffering from esophageal carcinoma received conventional fractionafiun radiotherapy,with 5 daily fractions of 2.0 Gy per week.The total radiation dose was 60 Gy.Concurrent chemotherapy dose escalation was given by the relatively safe and kidney-sparing modified Fibonacci sequence.The starting dose was cisplatin 37.5 mg/m~2 D1 and 5-fluorouracil 500 mg/m~2 D1-5, respectively.This regimen was repeated 4 times every 28 days.Escalation dose was eisplatin 7.5mg/m~2 and 5- fluorouracil 100mg/m~2.Every cohort contained at least 3 patients.If no dose-limiting toxicity(DLT)was observed, the next dose level was opened for entry.These courses were repeated until DLT appeared.MTD was declared as one dose level below which DLT appeared.Results DLT was defined as grade 3 radiation-induced esophngitis at the level of cisplatin 60 mg/m~2,5-fluorouracil 700 mg/m~2.MTD was defined as eisplafin 52.5 mg,/m~,5- fluorouracil 700 mg/m~2.The major side effect were radiation-induced esophagitis,leucopenia,nausea,vomiting and anorexia.Conclusion Maximun tolerated dose of cisplatin with 5-fluorouracil in concurrent chemoradiotherapy in the Chinese people with esophageal carcinoma were eisplatin 52.5 mg/m~2 D1,5-fluorouracil 700 mg/m~2 D1-5,repeated 4 times every 28 days.

SELECTION OF CITATIONS
SEARCH DETAIL
...